非酒精性脂肪性肝病药物治疗进展

Progress of Drug Treatment for Nonalcoholic Fatty Liver Disease

非酒精性脂肪性肝病(NAFLD)是一种无过量饮酒史和其他明确肝损害因素引起的以弥漫性肝细胞大泡性脂肪变为病理特征的疾病,主要包括单纯性脂肪肝、非酒精性脂肪性肝炎(NASH)、NASH相关性肝硬化三大类型,甚至最后发展肝细胞癌,因此关于NAFLD临床治疗方案的研究具有重要意义。目前已从临床用药实践中总结出了多种治疗NAFLD的药物,本文就NAFLD的药物治疗进展作一综述。

Nonalcoholic fatty liver disease （NAFLD） is a disease characterized by diffuse macrovesicular steatosis of liver cell without excessive drinking history or other factors of liver damage. It mainly includes simple fatty liver, nonalcoholic steatosis hepatitis （NASH）, NASH-related cirrhosis, and even finally development of hepatocellular carcinoma. Therefore, it is of great significance to study the clinical treatment of NAFLD. At present a variety of drug treatment for NAFLD has been formed. This article reviewed the progress of drug treatment for NAFLD.